Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.

Journal article

The identification of immunogenic cancer testis antigens (CTAs) as immunotherapeutic targets represents one approach to improve treatment options for diffuse large B-cell lymphoma (DLBCL). We previously identified PASD1 [PAS (Per ARNT Sim) domain containing 1 (PASD1)], a DLBCL-associated CTA that was expressed in a range of hematopoietic malignancies. The aim of the present study was to investigate the presence of a cytotoxic T-cell (CTL) response to PASD1 in DLBCL patients. A significant gam...

Expand abstract

Authors: Ait-Tahar, K; Liggins, A; Collins, G; Campbell, A; Barnardo, M

• Journal: British journal of haematology
• Volume: 146
• Issue: 4
• Pages: 396-407
• Publication date: 2009-08-01
• DOI: 10.1111/j.1365-2141.2009.07761.x
• EISSN: 1365-2141
• ISSN: 0007-1048
• Language: English
• Keywords: T-Lymphocytes; Adult; Fluorescent Antibody Technique; T-Lymphocytes, Cytotoxic; Histocompatibility Antigens Class I; Aged; Cytotoxicity Tests, Immunologic; Cell Line, Tumor; Lymphoma, B-Cell; Immunization; Lymphoma, Large B-Cell, Diffuse; Female; Middle Aged; HLA-A Antigens; HLA-A2 Antigen; Interferon-gamma; Humans; Antigens, Nuclear; Antigen Presentation; Young Adult; Aged, 80 and over; Male; Antigens, Neoplasm